N/A N=200 Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Diabetes Mellitus · Bipolar Disorder · Depression
Primary: Brief Psychiatric Rating Scale (BPRS) at 60 Weeks — 32.04; 35.89 scores on a scale — p=.785
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=152 Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy
Hypertension
Primary: Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Primary Endpoint — -10.6; -8.83; -0.5; -2.11 mmHg — p== 0.001
N/A N=506 Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis
Pancreatitis
Primary: Post ERCP Pancreatitis is the Primary Outcome. — 26; 20 participants — p=.45
Phase 2 N=33 F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
Mouth Neoplasms · Oropharyngeal Neoplasms · Laryngeal Neoplasms
Primary: Efficacy of Mean Pre-therapy FLT Uptake (SUVmean) in Predicting Progression Free Survival (PFS) — 4.23 standardized uptake value (SUV) — p=0.08
N/A N=99 Clinical Evaluation of DAILIES TOTAL 1® Performance in a Japanese Population
Refractive Error
Primary: Percentage of Subjects With Investigator-rated Lens Centration of "Optimal" After 10 Days of Wear — 89.5; 47.4 percentage of subjects
Phase 2 N=10 Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
Malignant Melanoma
Primary: Percentage of Participants That Experienced a Dose Limiting Toxicity (DLT) — 0; 17 percentage of participants
Phase 4 N=59 A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
Hepatitis C, Chronic
Primary: End of Treatment Response Rate at Week 72 in Genotype 1 — 68.2 Percentage of Participants
Phase 2 N=356 Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
Menopausal and Female Climacteric States
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) and Number of Participants With Mild, Moderate and Severe AE — 54; 52; 45; 51 Participants
Phase 3 N=91 A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
Allergic Conjunctivitis
Primary: Ocular Itching at Duration of Action (16 Hours + 1 Hour Post-dose) — 1.71; 2.34; 1.88; 2.50 units on a scale
Phase 3 N=272 Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Diabetes Mellitus, Type 1
Primary: Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide Area Under Curve [AUC] (Normalized for 120-minute Time Interval) at Month 12 — -0.21; -0.21 nanomoles per…
N/A N=150 Gastric Procedures for Obesity
Morbid Obesity
Primary: Change in Body Weight — -21.4; -36.6; -7.0 kg
Phase 2 N=303 Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies
Blood Cancer · Leukemia
Primary: Acute Graft vs Host Disease (GvHD) — 2.7 percentage of participants
N/A N=93 High-strength Glass-ionomer Dental Restorations
Dental Caries
Primary: Survival Rate — 39; 44; 5; 2 Restorations — p=0.262
Phase 3 N=77 Drug Treatment for Pathologic Gambling Disorder
Gambling
Primary: Yale-Brown Obsessive Compulsive Scale for Pathological Gambling (PG-YBOCS) — 16.9; 18.6; 9.7; 12.9 units on a scale
N/A N=141 Telephone Psychotherapy for Late-Life Generalized Anxiety Disorder (GAD)
Generalized Anxiety Disorder
Primary: Changes From Baseline in Penn State Worry Questionnaire (PSWQ-A) at Week 13 — -9.44; -5.37 units on a scale